As a Co-Founder of Aspiro Therapeutics, Julie Ledford leads the scientific direction to revolutionize the treatment of obstructive lung diseases.
Julie is an accomplished scientist with a distinguished track record in respiratory disease research and translational science. Her extensive background spans academic and industry settings, where she has successfully advanced therapeutic research and innovation. Julie is an expert in the role of endogenous lung proteins and how they mediate various states of lung inflammation, pathogen infection, and disease progression using pre-clinical animal models. Julie has contributed deep scientific knowledge specific to Aspiro’s assets and practice area, evaluating development strategies’ scientific merit and feasibility.
She plays a pivotal role in identifying and fostering partnerships with academic institutions, contract research organizations (CROs), and other relevant entities to accelerate the development and potential commercialization of the lead asset.